Gautam Swetlana, Roy Subhadeep, Ansari Mohd Nazam, Saeedan Abdulaziz S, Saraf Shubhini A, Kaithwas Gaurav
Department of Pharmaceutical Sciences, School of Biosciences and Biotechnology, Babasaheb Bhimrao Ambedkar University (A Central University), Vidya Vihar Raibereli Road, Lucknow, 226025, UP, India.
Department of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Kingdom of Saudi Arabia.
Breast Cancer. 2017 Mar;24(2):180-190. doi: 10.1007/s12282-016-0723-2. Epub 2016 Aug 24.
Cancer is a leading cause of death and major health concern worldwide. The animal and human studies support the presumption that inflammation directs the cancer initiation and progression. Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) are the key players in the inflammatory cascade contributing towards the angiogenesis, tumor cell invasiveness, and disruption in the pathways of cellular proliferation/apoptosis. Contemporary studies have particularized a promising role of COX-2 and 5-LOX inhibitors in cancer chemoprevention. The present review is a pursuit to define implications of dual COX-2 and 5-LOX (DuCLOX-2/5) inhibition on various aspects of cancer augmentation and chemoprevention.
癌症是全球主要的死亡原因和重大健康问题。动物和人体研究支持炎症指导癌症发生和发展这一推测。环氧化酶-2（COX-2）和5-脂氧合酶（5-LOX）是炎症级联反应中的关键参与者，它们促进血管生成、肿瘤细胞侵袭，并扰乱细胞增殖/凋亡途径。当代研究已明确COX-2和5-LOX抑制剂在癌症化学预防中具有前景广阔的作用。本综述旨在确定双重抑制COX-2和5-LOX（DuCLOX-2/5）对癌症发展和化学预防各方面的影响。
